# Pizarra — PT-pseudo_47c373e230b6 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47c373e230b6
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 75-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.27 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 8.3 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7478973 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.27. Prostate volume 41 mL. csPCa 0.75.

Vitals: weight 66 kg, height 180 cm, BMI 20.4, BP 122/66 mmHg, HR 73 bpm. Smoking: Ex-smoker (18 pack-yr, quit 2006).

Chief complaint: Ascending prostate-specific antigen readings and a history of a previously positive biopsy prompt this clinical assessment.

History: A 75-year-old male, formerly employed as a warehouse manager, first entered the diagnostic pathway in late 2022 due to an elevated prostate-specific antigen level. His medical background includes hypertension and hypercholesterolaemia, alongside benign prostatic hyperplasia. Current pharmacotherapy comprises amlodipine, valsartan, lisinopril, metoprolol, atorvastatin, simvastatin, and tamsulosin to address bothersome lower urinary tract symptoms. Tobacco use ceased in 2006 after an 18 pack-year accumulation. He continues a weekly swimming regimen. Although widowed, he resides with his partner who offers daily assistance, while his adult children stop by each week to manage paperwork. Recent visits to ophthalmology for cataract surveillance and a standard chest radiograph returned normal results. He denies experiencing fresh urinary blockage, blood in the urine, or skeletal discomfort, maintaining a stable International Prostate Symptom Score of 12.

Physical examination: Normal DRE: The gland demonstrates a smooth, firm consistency with symmetric enlargement and no palpable irregularities. Vital parameters remain stable: blood pressure registers at 122/66 mmHg with a regular cardiac rhythm of 73 bpm. General survey shows a well-nourished individual free of acute distress. Lung fields are clear, and abdominal palpation reveals a soft, non-tender contour.

Patient info: warehouse manager; Widowed; Lives with partner; adult children visit weekly.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 12 units / week; exercise Swimming 1x/week; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review; Radiology — chest X-ray (routine).
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.62 +/- 0.20   (95% CI 0.21-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=10.0, age=75.0, psad=0.27, dre_ord=0.0, vol=41.0, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.78 ng/mL/yr) against the prior PSA (8.3 ng/mL) and the current PSA (10.0 ng/mL), which suggests a rapid rise. It also could not incorporate the specific findings from the mpMRI report (PI-RADS 5) or the context provided by the previous positive biopsy status, which significantly alters the interpretation of the current PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests BIOPSY with a wide interval (0.62 +/- 0.20), indicating it is in the 'discuss' tier. This uncertainty is likely due to the conflict between the high csPCa probability (0.7478973) and the normal DRE findings. Furthermore, the prior does not account for the fact that the prior biopsy was positive, which changes the clinical question from "does he have cancer" to "is the cancer progressing/recurrent," making the initial suggestion potentially misaligned with the current clinical goal.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details specific suspicious lesions or features, it would refine the PI-RADS 5 interpretation.
  <document> PSA history (trend) -> If the trend shows a steeper rise or plateau, it would modify the urgency of the decision.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or follow-up plan.
  <document> laboratory results (full panel) -> This could provide context on other markers that might influence the risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_47c373e230b6", "radiology_report": "Subject: Prostate Multiparametric MRI | 05 February 2025 | Dept. of Radiology\n\nIndication: Surveillance for ascending prostate-specific antigen levels (10.0 ng/mL) and a previously positive biopsy outcome.\n\nImaging characteristics demonstrate a 41.0 mL organ with noticeable asymmetry. A discrete 14 mm focus occupies the left mid-gland peripheral zone. T2-weighted sequences show pronounced signal loss. Diffusion-weighted imaging confirms restricted movement alongside reduced apparent diffusion coefficient values. Dynamic contrast studies highlight early focal enhancement. The capsule remains intact without seminal vesicle encroachment, and pelvic nodes appear unremarkable.\n\nAssessment:\nPI-RADS 5 designation applies to the left mid-gland peripheral zone abnormality, spanning roughly 14 mm. With a gland size of 41.0 mL, the calculated PSA density stands at 0.27. The model estimates a csPCa probability of 0.7478973"}

  **psa_trend**
  {"case_id": "PT-pseudo_47c373e230b6", "psa_trend": [{"date": "Nov 2022", "val": 9.1}, {"date": "Aug 2023", "val": 2.8}, {"date": "May 2024", "val": 6.3}, {"date": "Feb 2025", "val": 10.0}]}

  **previous_notes**
  {"case_id": "PT-pseudo_47c373e230b6", "previous_notes": [{"date": "20 Feb 2023", "author": "Dr. P. van Dijk (GP)", "text": "November 2022 clinical records show an initial prostate-specific antigen reading of 4.2 ng/mL, which triggered the first diagnostic phase. Following a positive biopsy result indicating low-grade disease, he was directed to urology for detailed assessment. Subsequent care involved routine PSA tracking and yearly check-ups. The latest laboratory results reveal a continuing upward trajectory, necessitating this current review."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_47c373e230b6", "laboratory_results": [{"name": "PSA", "val": "10.0 ng/mL", "date": "02 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.65 ng/mL", "date": "02 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "02 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "15.6 g/dL", "date": "02 Jan 2025", "flag": ""}, {"name": "WBC", "val": "4.6 x10^9/L", "date": "02 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "216 x10^9/L", "date": "02 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "106 umol/L", "date": "02 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "02 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "17.8 nmol/L", "date": "02 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "108 U/L", "date": "02 Jan 2025", "flag": ""}, {"name": "LDH", "val": "176 U/L", "date": "02 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "6.5 %", "date": "02 Jan 2025", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - mpMRI report: PI-RADS 5 designation applies to the left mid-gland peripheral zone abnormality, spanning roughly 14 mm.
  - PSA trend: Rapid rise from 6.3 ng/mL (May 2024) to 10.0 ng/mL (Feb 2025), with a velocity of 1.78 ng/mL/yr.
  - csPCa predicted probability: 0.7478973

  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Previous biopsy status: Positive (None · Negative · ASAP/HGPIN · Positive)

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which contradicts the benign DRE and the prior positive biopsy. This leans towards a strong recommendation for further investigation.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly points toward sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which contradicts the normal DRE and the prior positive biopsy. The decision is driven by the PI-RADS 5 finding and the rapid PSA rise from 6.3 ng/mL to 10.0 ng/mL, which overrides the negative DRE and prior pathology.

Variables that carried weight: bx=decisive, age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
